Although the COVID-19 pandemic continues to affect our lives and communities as we approach the end of 2021, we are optimistic as vaccination rates rise and case counts decline, and we remain fully operational while keeping our team safe and our facilities open. Fortunately, our diversified product portfolio of FDA-approved brands is mitigating the impact of the pandemic on our business. 


Some key developments for our brands from this quarter include:

  • Implemented the national launch of our RediTrex® line of pre-filled methotrexate syringes, designed for the safe, simple treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis.
  • Published discussions with Dr. Ali Hassoun and Dr. Edward Dominguez regarding the Vibativ® dual mechanism of action and their thoughts on the product’s use in treating secondary bacterial infections in COVID-19 patients.
  • Announced a study supporting the use of Caldolor® in patients with kidney stones, while Dr. Stephen Southworth on a national podcast supported Caldolor as the foundational step in Enhanced Recovery After Surgery (ERAS) protocols as an alternative to opioids.
  • Distributed the Health Outcome Predictive Evaluation (HOPE) registry analysis regarding the need to treat hyponatremia in COVID-19 patients, supporting the use of Vaprisol®, which was discussed in a podcast with Dr. Biff Palmer.


Also in the third quarter, we released our 2020 Sustainability Report outlining our activities relating to environmental, social and governance (ESG) matters. Last year, we delivered nearly 2.5 million doses of our brands for patients, had no products recalled or studies terminated due to failure to practice good clinical standards, and had no brands listed on the FDA’s MedWatch Safety Alerts for Human Medical Products. Additionally, our workforce was 46% female and included 18% minorities. We remain committed to sustainability and to maintaining transparency of our corporate operations. 


We are working closely with clinical study sites as they reopen and enroll patients in trials for our products. We continue to develop our pipeline of treatments for unmet medical needs, which includes a new program for the use of our ifetroban to treat Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs).


Thanks to our team for their dedicated efforts in advancing our mission of improving patient care through the delivery of high-quality medicines. We are focused on that mission as we move through the final quarter of 2021, and we look forward to keeping you updated on our progress.